Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 and Ki67 in Apocrine Gland Anal Sac Adenocarcinoma.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Ki-67 Antigen*/metabolism ; Ki-67 Antigen*/genetics ; Adenocarcinoma*/metabolism ; Adenocarcinoma*/pathology ; Receptor, ErbB-2*/metabolism ; Apocrine Glands*/metabolism ; Apocrine Glands*/pathology ; Immunohistochemistry* ; Biomarkers, Tumor*/metabolism ; Anal Sacs*/metabolism ; Anal Sacs*/pathology; Humans ; Animals ; Dogs ; Female ; Male ; Anal Gland Neoplasms/metabolism ; Anal Gland Neoplasms/pathology

Apocrine gland anal sac adenocarcinoma is an aggressive neoplasm, and surgery remains the treatment of choice, although it is controversial in advanced cases. The prognostic factors are not well established. Human Epidermal Growth Factor Receptor 2 (HER2) is a membrane protein related to tumorigenesis, whereas Ki67 is a nuclear protein related to cell proliferation. Both are potential prognostic markers and therapeutic targets. This study aimed to evaluate the expression of HER2 and Ki67 markers in canine apocrine gland anal sac adenocarcinoma. The tumor samples were divided into four groups: largest tumor diameter less than 2.5 cm, largest tumor diameter greater than 2.5 cm, metastatic lymph nodes, and control group of non-neoplastic anal sacs. Each contained 10 samples. Immunohistochemistry was performed to verify the expression of HER2 and Ki67 markers. Positive HER2 staining was observed in 45% of the neoplastic cases and negative HER2 staining in 100% of the control group. The Ki67 expression had a median of 25% in all groups, except for the control group, which had a median of 8%. The HER2 and Ki67 expression was present in apocrine gland anal sac adenocarcinoma, making them potential therapeutic targets. However, it was not possible to determine the clinical value of either marker.

Cancer Metastasis Rev. 2015 Mar;34(1):157-64. (PMID: 25712293)
Cancer Metastasis Rev. 2016 Dec;35(4):575-588. (PMID: 27913999)
Vet Pathol. 2019 May;56(3):369-376. (PMID: 30612533)
Sci Rep. 2022 Jan 13;12(1):4. (PMID: 35027594)
Animals (Basel). 2021 Nov 22;11(11):. (PMID: 34828058)
Pathobiology. 2022;89(5):278-296. (PMID: 35500561)
Animals (Basel). 2021 Apr 03;11(4):. (PMID: 33916691)
Cancers (Basel). 2021 Mar 01;13(5):. (PMID: 33804398)
Transl Oncol. 2021 Nov;14(11):101205. (PMID: 34419682)
BMC Vet Res. 2013 Apr 20;9:83. (PMID: 23601191)
Vet Comp Oncol. 2021 Mar;19(1):92-98. (PMID: 32729979)
Semin Cancer Biol. 2021 Jul;72:123-135. (PMID: 32112814)
J Comp Pathol. 2013 Aug-Oct;149(2-3):199-207. (PMID: 23582973)
Animals (Basel). 2021 Jun 02;11(6):. (PMID: 34199347)
Vet Pathol. 2004 May;41(3):291-6. (PMID: 15133183)
Mol Med Rep. 2015 Mar;11(3):1566-72. (PMID: 25384676)
J Vet Med Sci. 2020 Jun 24;82(6):804-808. (PMID: 32249253)
Clin Cancer Res. 2016 Sep 1;22(17):4380-90. (PMID: 26994144)
Clin Cancer Res. 2019 Oct 1;25(19):5866-5877. (PMID: 31431454)
PLoS One. 2014 Jan 15;9(1):e85388. (PMID: 24454858)
J Am Vet Med Assoc. 2003 Sep 15;223(6):825-31. (PMID: 14507100)
J Vet Intern Med. 2007 Mar-Apr;21(2):274-80. (PMID: 17427388)
Arch Pathol Lab Med. 2014 Feb;138(2):241-56. (PMID: 24099077)
J Vet Med Sci. 2019 Jul 19;81(7):1034-1039. (PMID: 31142682)
Vet Comp Oncol. 2018 Dec;16(4):642-649. (PMID: 30246405)
J Vet Intern Med. 2020 Mar;34(2):873-881. (PMID: 31977135)
Trends Biochem Sci. 2018 Oct;43(10):747-748. (PMID: 30131191)
J Am Vet Med Assoc. 2018 Jul 1;253(1):84-91. (PMID: 29911942)
Cell Rep. 2018 Jul 31;24(5):1105-1112.e5. (PMID: 30067968)
Heliyon. 2019 Jul 17;5(7):e02004. (PMID: 31360780)
Cancer Treat Rev. 2014 Mar;40(2):276-84. (PMID: 24080154)
Vet Comp Oncol. 2018 Dec;16(4):518-528. (PMID: 29961964)
J Small Anim Pract. 2020 Mar;61(3):185-189. (PMID: 31960434)
Vet Comp Oncol. 2020 Dec;18(4):683-688. (PMID: 32266757)
J Small Anim Pract. 2017 May;58(5):263-268. (PMID: 28245066)
Sci Rep. 2021 Apr 27;11(1):9091. (PMID: 33907275)
Chromosoma. 2018 Jun;127(2):175-186. (PMID: 29322240)

Keywords: anal sac apocrine adenocarcinoma; immunohistochemistry; neoplasia; prognosis; therapeutic target

0 (Ki-67 Antigen)
EC 2.7.10.1 (Receptor, ErbB-2)
EC 2.7.10.1 (ERBB2 protein, human)
0 (Biomarkers, Tumor)

Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240717

20240717

PMC11203896

10.3390/ijms25126451

38928157